novo nordisk semaglutide products and competitors sued Eli Lilly, alleging misleading ads unfairly compare doses of Zepbound Mounjaro with Wegovy and Ozempic. Tap link in bio for full story Novo Nordisk (NVO) Stock Valuation

And to those people, I want to say its not your fault. The special also brought together for the first time two major competitors that are expanding the pharmaceutical weight loss drugs conversation: Negelle Morris, senior vice president, cardiometabolic sales of Novo Nordisk Inc., the Danish company behind Ozempic and Wegovy, and Rhonda Pacheco, group vice president of diabetes and obesity for Eli Lilly, the American pharma company that manufactures and sells Mounjaro and Zepbound

Semaglutides side effects are primarily digestive

Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes management and weight loss, and no antibiotics are contraindicated in its FDA prescribing information

It is advisable to limit alcohol consumption, and individuals should consult their trusted medical providers for personalized guidance